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systematic nutritional screening was undertaken on
admission. This study demonstrates which patients
receive enteral tube feeding and estimates the hospital
burden of such patients. METHODS: The CHKS hospi-
tal dataset contains aggregated, anonymised information
on diagnosis, hospital experience, and patient demo-
graphics for over 80 million episodes in the UK, repre-
senting 55% of hospital admissions. It was used to
identify patients who received enteral nutrition (using
OPCS-4 codes) and compared their hospital stays with a
control group who had the same primary diagnoses but
were not tube fed. Both groups were analysed for comor-
bidities, procedures, and length of stay (LOS). RESULTS:
We identiﬁed 14,328 patients who were tube fed in
2001/2002 out of 947,897 patients who were hospi-
talised for various diseases/conditions: dysphagia, cancer;
stroke; neurological, respiratory and GI disorders, cystic
ﬁbrosis, feeding difﬁculties/anorexia, renal disease, and
others. Tube fed patients had 28,768 separate episodes
compared to 2,502,937 episodes for patients having the
same disease/condition who did not receive any tube
feeds. Overall, tube fed patients had one additional pro-
cedure, i.e. the tube feeding procedure, during their 
hospital stay compared to controls (average of 2.3 
procedures across disease groups for tube fed patients).
Daily tube feeding costs vary between £10.20 and
£13.18. This represents only 2.8–3.6% of the daily inpa-
tient cost of, for example, £359 in a surgical ward. CON-
CLUSIONS: Over 26,000 patients who are tube fed 
are admitted yearly in England. However the number of
patients receiving tube feeding is very restricted, even
though the cost is a small fraction of hospital costs. Does
every patient who could beneﬁt from tube feeding receive
it? If not, should tube feeding remain severely restricted
when it is known that its use could improve patients’
recovery?
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OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) computes payment for high cost new tech-
nology drugs and biologicals in the hospital outpatient
prospective payment system (OPPS) under two methods.
This study examines the results of CMS computations
over the initial thirty months of the hospital outpatient
prospective payment system. METHODS: Phase I: CMS
methods used ﬁrst for payment of high cost new tech-
nology drugs and biologicals eligible for initial pass-
through payment status and second for subsequent
expired pass-through payment status were identiﬁed.
Underlying assumptions were examined and formal
methodology evaluations were collected. Phase II: A
thirty-month time line was constructed. The assumptions
utilized for CMS changes in payment status at month one,
month nineteen and month twenty-eight were examined
and analyzed. Analyses employing descriptive statistics
identiﬁed components of payment assumptions and vari-
ations between the assumptions utilized at each of the
three time line milestones. Findings were compared to a
sample of actual CMS payments received by hospitals.
RESULTS: A database of methodology explanations,
visuals, and evaluations was created. An evolutionary
time line of CMS methodologies and underlying assump-
tions was created. Study analyses revealed a statistically
signiﬁcant differential between aggregated mean payment
amounts for the same high cost new technology drugs and
biologicals at the ﬁrst and the third milestones of the time
line. Over one-half of the affected drugs and biologicals
sustained payment rate reductions exceeding forty
percent. CONCLUSIONS: CMS payment methods and
underlying assumptions for expired pass-through drugs
and biologicals is ﬂawed. In addition, the basic hospital
drug acquisition cost assumptions made by CMS are not
consistent with actual hospital data. These ﬁndings will
be of use to economists, cost accountants, and policy
makers interested in arriving at equitable payments for
high cost new technology drugs that are essential to
modern health care in U.S. hospitals.
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OBJECTIVES: This outlines the lessons learned by the
author who is Director of one of the six units in the 
UK that undertake independent academic evaluations of
Technology Assessment Reviews for NICE. The author
provides an insiders’ view of the major issues that arise
in managing the evaluation process. METHODS: The
Liverpool TAR group assists NICE to provide guidance
on appropriate treatment for speciﬁc conditions in spe-
ciﬁc sub-groups of patients. The aim is to standardise clin-
ical practice around the most clinically and cost-effective
interventions. The aim is to spread cost-effective new
treatments more quickly across the health service to
promote successful innovation on the part of the phar-
maceutical industry. The importance of this UK initiative
goes beyond its national borders as other governments 
are guided by NICE judgements in their reimbursement
decisions and many are developing similar systems of
appraisal. RESULTS: The paper analyses the impact of
the 6-stage structure of NICE evaluation and assesses
how generalisable the process may be to other countries.
Issues underlying the targeting of NICE appraisals will
also be examined together with the challenges presented
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to the pharmaceutical industry by the NICE initiative.
Although it remains a fairly recent innovation, it would
appear to be timely to undertake an initial assessment of
its implications, both for the pharmaceutical industry and
for national health systems. CONCLUSIONS: The nature
and extent of the learning process through which NICE
has progressed will be explored, together with the current
state of the art with regard to NICE evaluation. In addi-
tion, the potential beneﬁts that arise to health services
from a NICE-style appraisal process will be presented.
Methods by which the clinical and economic evaluations
can be integrated will be presented.
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OBJECTIVES: To select medical technologies that should
be provided to the general public under the National
Health Law. The rapid development of new technologies
and the limited budget of the health care system make the
selection process difﬁcult. The research focused on the
Israeli National Health Care System that faces budgetary
constraint. Once a year a ﬁxed budget has to be allocated
among a set of candidate technologies. The constraint
imposed by the ﬁxed budget must be taken into account
in the decision-making process. METHODS: We devel-
oped a Group Decision Support System based on a 
three-dimensional model: 1) Beneﬁt (measured by the
effectiveness of each technology); 2) Risk (measured by
EBM); and 3) Cost: Based on the Analytical Hierarchy
Process (AHP) methodology, a set of criteria was devel-
oped by a group of medical experts, economists, patient
representatives, sociologists, law experts and ethical
experts. EBM was used to assess the Risk (knowledge
gap) associated with each alternative. While Cost was
estimated by explicit market price of the technology in
consideration. RESULTS: A set of candidate medical
technologies evaluated by the proposed methodology
revealed a clear Pareto distribution. The proposed
methodology helped the decision-makers focus on the
most promising technologies out of a total 193 technolo-
gies proposed. CONCLUSIONS: The proposed method-
ology helped decision makers by focusing their attention
on the most promising medical technologies based on pre-
deﬁned objective set of criteria. The decision process is
more effective and it achieves higher efﬁciency by using
the Group Decision Support System (GDSS).
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The accuracy and reliability of genetic tests has been
rapidly improving, while the cost of such tests is becom-
ing more affordable. The implications of this are poten-
tially drastic: individuals will have access to information
about their genetic predispositions, allowing them to alter
their decisions accordingly. One consideration in this is
the demand for life insurance: an individual at genetic risk
may be inclined to purchase more life insurance in order
to protect her family’s future; however, insurance com-
panies may also try to exclude “bad genetic risks”, assum-
ing they have access to that information. Both actions
lead to adverse selection and inefﬁciency problems in the
insurance market. This paper focuses on the implica-
tions of genetic testing for breast cancer genes (BRCA1
and BRCA2) on life insurance markets. Mutations on
BRCA1/2 genes are not a deﬁnite predictor of breast
cancer: there is roughly an 85% lifetime probability that
a carrier will develop the disease, moreover, individuals
can use prophylaxis and thereby considerably lower their
risk of developing breast cancer. Hence, the interpretation
of a positive test result is complicated, both for the indi-
vidual and for the insurance company. OBJECTIVE: This
paper looks at several scenarios (including different 
age and risk groups and income levels) to determine the
impact on the demand for life insurance by women at
genetic risk for breast cancer. METHOD: The methodol-
ogy used is a microeconomic framework where individ-
uals maximise their expected utility as a function of
insurance purchases, and the insurance company may or
may not know the results of the genetic test. RESULTS:
The results show that women with higher incomes and
higher levels of risk aversion are more likely to purchase
life insurance. CONCLUSIONS: However, women that
are less risk averse and have lower incomes tend to under-
insure themselves, underscoring the need to ensure an
adequate perception of own-risk.
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OBJECTIVE: As part of an “outcomes program” on
smoking cessation, we thought it relevant to evaluate in
smokers under 25 years of age the obstacles to cessation,
the level of dependency, the knowledge of tobacco depen-
dency and the propensity to pay for cessation treatment.
METHOD: For this pilot phase, an anonymous ques-
tionnaire was distributed in the “Etudiant” supplement
of a French regional weekly newspaper. RESULTS:
Obstacle to cessation: lack of willpower (51%), enjoy-
ment of smoking (32%), force of habit (46%) The level
of dependency on tobacco was evaluated using the Fager-
ström test: 48% had low dependency, 48% moderate
